Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded rat hippocampal region tissue from a model with Alzheimer)
WB (Western Blot) (Western blot analysis of extracts from mouse brain tissue using Tau(Phospho-Ser396) Antibody and the same antibody preincubated with blocking peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
Pricing
WB (Western Blot) (Western blot analysis of VEC using p-cPLA2 (S505) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using 4E-BP1(Phospho-Thr45) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells using 4E-BP1(Phospho-Thr45) Antibody and the same antibody preincubated with blocking peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IP (Immunoprecipitation) (Detection of human Phospho-MEK1 (T286) by immunoprecipitation (IP). Samples: 50 ug HeLa whole cell lysate (WCL) from mock treated (-) or nocodazole treated (+) cells. 1 mg of HeLa WCL mock treated (-) or nocodazole treated (+) and immunoprecipitated; 20% of the IP was loaded. Antibodies: Affinity purified goat anti-phospho MEK1 (T286) AAA212238 was used for IP (6ug/1mg lysate). To detect total MEK1, Rabbit anti-MEK1 (BL8445) was used for western blot (WB) at 1 ug/ml. Detection: Chemiluminescence with exposure time of 30 seconds.)
IHC (Immunohiostchemistry) (Detection of mouse Phospho-MEK1 (T286) by immunohistochemistry. Sample: FFPE section of mouse teratoma. Antibody: Affinity purified goat anti-phospho MEK1 (T286) (Cat. No. AAA212238 lot 1) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB)
IHC (Immunohistochemistry) (Detection of human Phospho-MEK1 (T286) by immunohistochemistry. Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified goat anti-phospho MEK1 (T286) (Cat. No. AAA212238 lot 1) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of HSP27 (pS15) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of HSP27 (pS15) expression in HeLa Anisomycin-treated (A), MCF7 (B) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of S6K1 (pT421) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of S6K1 (pT421) expression in MDAMB231 insulin-treated (A), Jurkat (B), HeLa (C), NIH3T3 (D), PC12 (E) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Ezrin (pT567) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Ezrin (pT567) expression in HeLa (A), A431 (B), SHSY5Y (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of LCK (pY393) staining in MCF7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).)
WB (Western Blot) (Western blot analysis of LCK (pY393) expression in MCF7 TNFa-treated (A), mouse liver (B), rat liver (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of ETS1 (pT38) staining in Jurkat cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of ETS1 (pT38) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of ETS1 (pT38) expression in LO2 (A), Jurkat (B), HepG2 (C), NIH3T3 (D), rat liver (E) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IKK beta (pY188) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IKK beta (pY188) expression in HeLa LPS-treated (A), Raw264.7 LPS-treated (B), PC12 LPS-treated (C) whole cell lysates.)
Western Blot, Immunohistochemistry, Immunofluorescence, Immunocytochemistry
Pricing
WB (Western Blot) (Western blot analysis of extracts from 293 cells. Jurkat cells and NIH/3T3 cells all treated with Paclitaxel, using BCL2 (Phospho-Ser70) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using FER (Phospho-Tyr402) antibody. Western blot analysis of extracts from Jurkat cells, treated with starved (24hours), using FER (Phospho-Tyr402) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (Immunofluorescent analysis of MKK4 (pT261) staining in NIH3T3 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of MKK4 (pT261) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of MKK4 (pT261) expression in NIH3T3 PDGF-treated (A) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of PLC gamma 2 (pY753) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of PLC gamma 2 (pY753) expression in Hela TNFa-treated (A), MCF7 (B), Raw264.7 TNFa-treated (C), mouse kidney (D), rat kidney (E) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IKK gamma (pS85) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IKK gamma (pS85) expression in THP1 LPS-treated (A), Raw264.7 LPS-treated (B), rat brain (C) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of DOK2 (pY299) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of DOK2 (pY299) expression in A549 Insulin-treated (A), HepG2 (B) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of S6K1 (pS418) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of S6K1 (pS418) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of S6K1 (pS418) expression in NIH3T3 (A), HeLa (B), KNRK (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of p53 (pS15) staining in PC12 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of p53 (pS15) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of p53 (pS15) expression in HeLa UV-treated (A), PC12 (B) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of c-CBL (pY674) staining in human cervical cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of c-CBL (pY674) expression in HeLa EGF-treated (A), mouse liver (B), rat liver (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of Alpha-adducin (pS726/713) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).)
WB (Western Blot) (Western blot analysis of Alpha-adducin (pS726/713) expression in HeLa (A), SP2/0 (B), PC12 (C) whole cell lysates.)
WB (Western Blot) (P-peptide-+ Western blot analysis of extracts from HepG2 cells, treated with Adriamycin (0.5uM, 5hours), using Ataxin 1 (Phospho-Ser776) antibody. Immunofluorescence analysis of NIH/3T3 cells, using Ataxin 1 (Phospho-Ser776) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (HepG2 cells were subjected to SDS PAGE followed by western blot with AAA249539(Phospho-GSK3B (Ser9) antibody) at dilution of 1:1000)
IF (Immunofluorescence) (Immunofluorescent analysis of HepG2 cells using AAA249539(Phospho-GSK3B (Ser9) antibody) at dilution of 1:50.)
IHC (Immunohistochemistry) (Immunohistochemistry of paraffin-embedded human liver cancer tissue slide using AAA249539(Phospho-GSK3B (Ser9) Antibody) at dilution of 1:100)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun(Phospho-Ser243) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from sorbitol-treated 293, Serum-treated C2C12 and UV-treated HepG2 cells using c-Jun(Phospho-Ser243) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ATF2(Phospho-Thr71 or 53) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HUVEC cells untreated or treated with Anisomycin using ATF2 (Phospho-Thr71 or 53) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ATF2(Phospho-Ser112 or 94) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Huvec cells untreated or treated with Anisomycin using ATF2(Phospho-Ser112 or 94) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using EGFR(Phospho-Ser1070) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HUVEC cells untreated or treated with EGF using EGFR(Phospho-Ser1070) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using CDC2(Phospho-Thr161) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated(lane 1) or treated with UV(lane 2) using CDC2(Phospho-Thr161) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using cdc25A(Phospho-Ser76) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with TNF-a and CA using cdc25A(Phospho-Ser76) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Zap-70(Phospho-Tyr493) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from JK cells untreated or treated with anisomycin using Zap-70(Phospho-Tyr493) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using PKCth(Phospho-Ser695) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with PMA using PKCth(Phospho-Ser695) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using SEK1/MKK4(Phospho-Thr261) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using SEK1/MKK4(Phospho-Thr261) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MEK1/MEK2(Phospho-Ser217/Ser221) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cell untreated or treated with UV MEK1/MEK2(Phospho-Ser217/Ser221) Antibody)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using IkB-e(Phospho-Ser22) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with TNF using IkB-e(Phospho-Ser22) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MEF cells untreated or treated with IFN using STAT3 (Phospho-Tyr705) Antibody.)
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded human Lung carcinoma tissue using STAT3 (Phospho-Tyr705) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using STAT3 (Phospho-Tyr705) Antibody (left) or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with IFN a using STAT3(Phospho-Tyr705) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from SK-BR-3 cells,treated with insulin and EGF, and pretreated with U0126and LY294002 cells using Akt (Phospho-Ser473) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treatedwith EGF or calf intestinal phosphatase (CIP), using Akt(Phospho-Ser473) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Akt(Phospho-Ser473) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells, treated with calf intestinal phosphatase (CIP), using HDAC2 (Phospho-Ser394) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells showing nuclear staining using HDAC2(Phospho-Ser394) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HDAC2(Phospho-Ser394) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with EGF using HDAC2(Phospho-Ser394) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from JK cells, treated with G-CSF or calf intestinal phosphatase (CIP), using p56Dok-2 (Phospho-Tyr299) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using p56Dok-2(Phospho-Tyr299) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using p56Dok-2(Phospho-Tyr299) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells untreated or treated with insulin using p56Dok-2(Phospho-Tyr299) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue, using eIF2alpha (Phospho-Ser49) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using eIF2a(phospho-Ser49) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using eIF2alpha (Phospho-Ser49) Antibody (left) or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with starvation using eIF2a(phospho-Ser49) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin- embedded human lung carcinoma tissue using NFκB-p65 (Phospho-Ser276) antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin- embedded human breast carcinoma tissue using NFκB-p65 (Phospho-Ser276) antibody.)
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFκB-p65 (Phospho-Ser276) Antibody (left) or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extract from Hela cells using NF-κB p65 (phospho-Ser276) antibody. Lane 1: The antibody is not preincubated with blocking peptides. Lane 2: The antibody is preincubated with non- phospho peptide blocking peptides. Lane 3: The antibody is preincubated with phospho peptide blocking peptides.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using NFκB-p65 (Phospho-Ser276) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence analysis of NIH/3T3 cells, using 53BP1 (Phospho-Ser25) antibody. The picture on the right is treated with the synthesized peptide.)
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using 53BP1 (Phospho-Ser25) antibody. The picture on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells (Lane 2), using DYN1 (Phospho-Ser778) Antibody. The lane on the left is treated with synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from Mouse brain cells, using DYN1 (Phospho-Ser778) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using WAVE1 (Phospho-Tyr125) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from NIH/3T3 cells, treated with Insulin (0.01U/ml, 15mins), using WAVE1 (Phospho-Tyr125) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from C6 cells, treated with PMA or calf intestinal phosphatase (CIP), using c-Jun (Phospho-Ser73) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun(Phospho-Ser73) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from PC14 cells untreated or treated with EGF using c-Jun(Phospho-Ser73) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.